EXPERIENCE

RESULTS:

ACCELERA BIOLOGICS

ACCELERA EXPERTISE

An increasing number of biological agents are being developed as therapeutics, prompting the interest of many pharmaceutical and biotech companies in laboratory techniques and specific animal models.

At Accelera, our dedicated Analytical Biology unit focuses on bioanalysis and immunogenicity testing of different biological drug products, such as bioactive recombinant proteins/peptides, therapeutic monoclonal antibodies, as well as oligonucleotides and gene therapeutics, providing an extensive battery of state-of-the-art technologies and GLP-compliant services.

Our animal facility, which accommodates rodent and non-rodent animal species, including non-human primates combined with Accelera’s Toxicology, ADME and PK capabilities, allows the execution of several integrated studies (e.g. PK/PD, repeated toxicity studies with TK) and service packages (e.g. IND enabling pre-clinical studies) to support the development of new biotherapeutics.

Leading experts are working in Accelera to provide services and scientific advice in special technology areas, including:
- Preformulation
- Cardiovascular Safety Pharmacology
- Drug-drug interactions
- In vitro DART
- Infusion Technologies in NHP
- LC-MS/MS of proteins
- ELISA
- Electron Microscopy
- Immunohistochemistry
- Radiosynthesis
- QWBA
- PBPK and PK/PD Modelling
- Population PK

Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies around the world we provide highly qualified Pre-clinical, Biologics and Small Molecules Services so you can rely on us as your preferred Drug Development Partner.

We support all stages of the drug discovery and development process. We offer integrated services, including Attrition Reducing Technologies (ART) and Toxicology Screening to help you “pick the best” drug candidates. We also offer Regulatory Drug Safety, Safety Pharmacology, ADME, Bioanalysis and Pharmacokinetic studies to translate new chemical entities and biotherapeutics into novel medicines.

We are confident you will find at Accelera, a unique platform of integrated scientific, technological and regulatory expertise, built on decades of experience in the international pharmaceutical industry ready to fit into your business and technical requirements.
EXPERIENCE
RESULTS:
ACCELERA

ACCELERA provides support services and consultancy to develop both New Chemical Entities (NCEs) and biologics as new oncology drugs through Accelera Oncology, a dedicated team of experts in preclinical tumor models, PK/PD, Attrition Reducing Technologies (ART), Drug Safety, Bioanalysis and Regulatory Development. Accelera Oncology represents a unique combination of product development experience from cytotoxics to molecular targeted therapeutics, gained over time as an R&D site of major pharmaceutical companies (Pharmacia, Pfizer), and in collaboration with the leading clinical oncology centers in Europe and the USA.

Accelera Oncology experts are available to assess the status of your oncology program, and to provide advice and input to optimize drug development strategies. Please contact us if you would like to learn how Accelera can help accomplish the challenges of your programs, request a quotation or just ask for more information about our services. We would be pleased to arrange a visit by one of our representatives. Or better still, why not come to Milan and let us show you around the Accelera facilities? We hope to hear from you soon.

EXPERIENCE
RESULTS:
ACCELERA BIOLOGICS

An increasing number of biological agents are being developed as therapeutics, prompting the interest of many pharmaceutical and biotech companies in laboratory techniques and specific animal models. At Accelera, our dedicated Analytical Biology unit focuses on bioanalysis and immunogenicity testing of different biological drug products, such as bioactive recombinant proteins/peptides, therapeutic monoclonal antibodies, as well as oligonucleotides and gene therapeutics, providing an extensive battery of state-of-the-art technologies and GLP-compliant services.

Our animal facility, which accommodates rodent and non-rodent animal species, including non-human primates combined with Accelera’s Toxicology, ADME and PK capabilities, allows the execution of several integrated studies (e.g. PK/PD, repeated toxicity studies with TK) and service packages (e.g. IND enabling pre-clinical studies) to support the development of new biotherapeutics.

Leading experts are working in Accelera to provide services and scientific advice in special technology areas, including:

- Preformulation
- Cardiovascular Safety Pharmacology
- Drug-drug interactions
- In vitro DART
- Infusion Technologies in NHP
- LC-MS/MS of proteins
- ELISA
- Electron Microscopy
- Immunohistochemistry
- Radiosynthesis
- QWBA
- PBPK and PK/PD Modelling
- Population PK

SPEED UP YOUR TIME TO MARKET

#Pre-clinical
#Biologics
#Small molecules

Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies around the world we provide highly qualified Pre-clinical, Biologics and Small Molecules Services so you can rely on us as your preferred Drug Development Partner. We support all stages of the drug discovery and development process. We offer integrated services, including Attrition Reducing Technologies (ART) and Toxicology Screening to help you “pick the best” drug candidates. We also offer Regulatory Drug Safety, Safety Pharmacology, ADME, Bioanalysis and Pharmacokinetic studies to translate new chemical entities and biotherapeutics into novel medicines.

We are confident you will find at Accelera, a unique platform of integrated scientific, technological and regulatory expertise, built on decades of experience in the international pharmaceutical industry ready to fit into your business and technical requirements.
Discovery

Bioanalysis

Development

TARGET

Discovery Reducing Technologies (ART)

Toxicology Screening

IND enabling Packages

Safety Pharmacology

Chronic Toxicology

Developmental and Reproductive Toxicology (DART)

Clinical Bioanalysis & Pharmacokinetics

PK/PD Modelling

Translational Sciences

Isotope Chemistry/Drug Disposition

Metabolite Profiling and Identification

Regulatory Consultancy & Documentation

ACCELERA INTEGRATED SERVICES
ACCELERA
INTEGRATED SERVICES

- Attrition Reducing Technologies (ART)
- Toxicology Screening
- IND enabling Packages
- Safety Pharmacology
- Chronic Toxicology
- Developmental and Reproductive Toxicology (DART)
- Clinical Bioanalysis & Pharmacokinetics
- PK/PD Modelling
- Translational Sciences
- Isotope Chemistry/Drug Disposition
- Metabolite Profiling and Identification
- Regulatory Consultancy & Documentation
EXPERIENCE

RESULTS:

ACCELERA
ONCOLOGY

Accelera provides support services and consultancy to develop both New Chemical Entities (NCEs) and biologics as new oncology drugs through Accelera Oncology, a dedicated team of experts in preclinical tumor models, PK/PD, Attrition Reducing Technologies (ART), Drug Safety, Bioanalysis and Regulatory Development.

Accelera Oncology represents a unique combination of product development experience from cytotoxics to molecular targeted therapeutics, gained over time as an R&D site of major pharmaceutical companies (Pharmacia, Pfizer), and in collaboration with the leading clinical oncology centers in Europe and the USA.

Accelera Oncology experts are available to assess the status of your oncology program, and to provide advice and input to optimize drug development strategies.

Please contact us if you would like to learn how Accelera can help accomplish the challenges of your programs, request a quotation or just ask for more information about our services.

We would be pleased to arrange a visit by one of our representatives. Or better still, why not come to Milan and let us show you around the Accelera facilities?

We hope to hear from you soon.
An increasing number of biological agents are being developed as therapeutics, prompting the interest of many pharmaceutical and biotech companies in laboratory techniques and specific animal models.

At Accelera, our dedicated Analytical Biology unit focuses on bioanalysis and immunogenicity testing of different biological drug products, such as bioactive recombinant proteins/peptides, therapeutic monoclonal antibodies, as well as oligonucleotides and gene therapeutics, providing an extensive battery of state-of-the-art technologies and GLP-compliant services.

Our animal facility, which accommodates rodent and non-rodent animal species, including non-human primates combined with Accelera’s Toxicology, ADME and PK capabilities, allows the execution of several integrated studies (e.g. PK/PD, repeated toxicity studies with TK) and service packages (e.g. IND enabling pre-clinical studies) to support the development of new biotherapeutics.
Leading experts are working in Accelera to provide services and scientific advice in special technology areas, including:

- Preformulation
- Cardiovascular Safety Pharmacology
- Drug-drug interactions
- In vitro DART
- Infusion Technologies in NHP
- LC-MS/MS of proteins
- ELISA
- Immunohistochemistry
- Radiosynthesis
- QWBA
- PBPK and PK/PD Modelling
- Population PK